The EpiShuttle is approved by the Therapeutic Goods Administration (TGA) and is now fully available for use in the Australian market.
“Even though The EpiShuttle has been with RAAF for some time now, we are happy to see that the safe isolation and transport system now fully available to the civil Australian market,” says Michael Eimstad, CEO at EpiGuard.
Australia is known for its long distances which often require the use of air ambulances.
During trials to certify the PC-24’s impressive unpaved runway capabilities, aircraft manufacturer Pilatus prioritized the requirements of the Royal Flying Doctor Service of Australia. A key early customer for the Swiss twinjet, the RFDS helped establish the PC-24’s credentials as an air ambulance.
“The approval allows the EpiShuttle to be an important asset to Australian medical providers, enabling them to transport infectious patients safely and efficiently in emergency situations”, Eimstad said.
Viral outbreaks occur more frequently now than before. During epidemics there are hotspots with ICU capacity brought to its knees. Safe isolation and transport are therefore kernel to the strategy of pandemic preparedness. “During outbreaks we must be able to transport patients out of hotspots to where ICU capacity is available. Only when safe transport is in place can we utilize the full capacity of the entire health care system and ensure treatment for everyone,” Eimstad concluded.
EpiShuttles are used by WHO as well as first responders in Germany, Belgium, Denmark, Peru, Ireland, Greece, Norway, and the UK. Also, national air forces like the Australian, Canadian, Danish, Norwegian and others are equipped with EpiShuttles. In the private sector, EpiShuttles are a common sight amongst companies like FAI air ambulance, Air Alliance Medflight, DRF Luftrettung, Keewatin Air, Luxemburg Air Rescue and others. The EpiShuttle is NATO stock listed and CE-marked as a class one medical device.
Photo of the EpiShuttle: DRF Luftrettung